Geographic Variation in Costs Associated With Hysterectomy

Share this content:
Geographic Variation in Costs Associated With Hysterectomy
Geographic Variation in Costs Associated With Hysterectomy

FRIDAY, April 14, 2017 (HealthDay News) -- There is considerable geographic variation in the cost of hysterectomy, according to a study published in the May issue of Obstetrics & Gynecology.

David Sheyn, M.D., from the University Hospitals Cleveland Medical Center, and colleagues evaluated data for 38,414 women undergoing inpatient hysterectomy for benign indications from the 2013 Healthcare Cost and Utilization Project National Inpatient Sample. The authors sought to examine geographic variation in the cost associated with hysterectomy.

The researchers found that hysterectomy had a median cost of $13,981. The lowest median cost was seen in the mid-Atlantic region ($9,661), while the highest median cost was seen in the Pacific region ($22,534). The highest probability of costs above the median were seen for the Pacific, South Atlantic, and South Central regions, compared with the mid-Atlantic region (adjusted odds ratios [aORs], 10.43 [95 percent confidence interval (CI), 9.44 to 11.45], 5.39 [95 percent CI, 4.95 to 5.86], and 2.40 [95 percent CI, 2.21 to 2.62], respectively). All concomitant procedures correlated with elevated cost apart from bilateral salpingectomy (aOR, 1.03; 95 percent CI, 0.95 to 1.12). The probability of increased costs was higher for laparoscopic and robotic modes of hysterectomy versus vaginal hysterectomy (aORs, 2.86 [95 percent CI, 2.61 to 3.15] and 5.66 [95 percent CI, 5.11 to 6.26]).

"The cost of hysterectomy varies significantly with geographic region after adjusting for confounders," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »